NATURAL FORMULATION FOR THE TREATMENT AND PREVENTION OF DEPRESSION, CONTAINING ST JOHN'S WORT AND DERIVATIVES OF DIHYDRO- AND TETRAHYDROFOLIC ACID

Abstract: The present invention relates to novel compositions containing a combination of the plant St. John's Wort (Hypericum perforatum L.), its extracts of active ingredients and derivatives of dihydro- and tetrahydrofolic acid. This natural formulation is useful for the treatment and prevention of depression with a better effect than the ingredient compounds alone.

Description: NATURAL FORMULATION FOR THE TREATMENT AND PREVENΗON OF DEPRESSION, CONTAINING ST JOHN'S WORT AND DERIVATIVES OF DIH DRO- AND TETRAHYDROFOLIC ACID The present invention relates to novel compositions containing a combination of the plant St. John's Wort (Hypericum perforatum L) and derivatives of folic acid. This natural formulation is useful for the treatment and prevention of depression with a better effect than the ingredient compounds alone. Depression is an increasingly common psychiatric disorder, affecting a large part of the population, especially in developed countries. The etiology and 10 precise mechanisms of depressive disorders are not completely understood, but are believed to involve the decrease of certain neutrotransmitters, particularly serotonin (5-HT) and its metabolite, 5-hydroxyindole acetic acid (5- HIAA) in the central nervous system. High level of homocysteine and both folate and vitamin B12 deficiency are also linked to the etiology of depres¬ 15 sion. Modern standard pharmacological antidepression agents can be divided into several major groups: selective serotonin reuptake inhibitors, tricyclic and other heterocyclic antidepressants, monoamine oxidase (MAO) inhibitors, etc. 20 All of them provoke a wide range of adverse effects - from undesirable psy- chostimulation to hypertension and cardiotoxicity. Despite some progress in this area and the availability of new antidepressants with fewer side effects, this direction of research has not granted a safe ? - and efficient way to treat depression. Therefore, there is a need for an innovative formulation based on the natural metabolites useful for the prevention and treatment of depression. Now it has been found that the combination of natural compounds - St. 30 John's Wort or its extracts or active ingredients and folic acid derivatives - constitutes a unique safe multifaceted approach to the prevention and treatment of mild to moderate forms of depression. St. John's Wort is a perennial flowering plant that has been traditionally used in folk medicine for thousands of years due to its anti-inflammatory, analgesic 35 and sedative properties, particularly for wound healing and treatment of respiratory infections (see Miller, A.L., 1998, Altern. Med. Rev. 3,1 ,18-26). Recently it attracted attention as an effective agent for the treatment of mild to moderate depression and also of the seasonal affective disorder. Other indications include psychovegetative dysfunctions, anxiety, nervous restlessness and similar disorders. About 30 clinical studies confirmed that the effi- cacy of St. John's Wort (SJW) is compared to popular synthetic antidepres- sion agents (amitriptyline, imipramine, maprotiline, etc.) without any side effects (see Lieberman, S., 1998, Altern. Complement. Therapies, June, 163- 168). It did not lead to the impairment of attention, concentration or reaction. The only side effect mentioned in the literature is the reversible increased photosensitivity to UV light after prolonged use of the St. John's Wort extract (see Golsch, S. et al., 1997, Hautarzt 48, 4, 249-252). No negative drug interaction associated with St. John's Wort is reported. The mechanism of action of SJW is not completely defined. In its extract there could be identified eight secondary metabolites so far: amentoflavone, biapigenin, hyperforin, hypericin, hyperosid, pseudohypericin, quercetin and rutin (see Buter, B. et al., 1998, Planta Med. 64, 5, 431-437). There are indications that hypericin, one active compound from SJW is a strong inhibitor of catechol-O-methyltransferase (see Mueller, W.E.G. et al., 1994, J. Geriatr. Psychiatr. Neurol. 7(Suppl. 1), 63-64; Mueller, W.E.G., 1995, Wissenschaftlicher Bericht, Lichtwer Pharma GmbH, Berlin) and monoamine oxidases (see Suzuki, O. et al., 1984, Planta Med. 50, 272-274). Monoamine oxidases participate in the breakdown of neurotransmitters serotonin and noradrenalin (see Perovic, S. et al., 1995, Arzn. Forsch/Drug Res. 45, 1145- 1148). Further effects include the modulation of the serotonin receptors or/and a general influence of hypericum extracts on central dopaminerge neurons (see Butterweck, V. et al., 1998, Planta Med. 64, 4, 291-294). Other reports suggest that since pure hypericin shows no inhibiting effect on MAO (see Bladt, S. et al., 1994, J. Geriatr. Psychiatr. Neurol. 7, Suppl. 1 , 57- 59), the antidepressive effect of SJW cannot be explained in terms of MAO inhibition. In a series of recent publications it has been demonstrated that hy- perforin, a major lipophilic non-nitrogenous constituent of SJW (and of Hy- perici Oleum), is also a potent inhibitor of uptake of serotonin, dopamine, noradrenaline, GABA, and L-glutamate in vitro (see Chattarjee, S.S. et al., 1998, Life Sci. 63, 6, 499-510). Most of the known pharmacological properties of the SJW extract can also be demonstrated with pure hyperforin. Therefore it has been suggested that hy- perforin could be a major active principle of the plant (see Laakmann, G. et al., 1998, Pharmacopsychiatry 31 , Suppl. 1 , 54-59). Most researchers agree that the combination of low-grade monoamino oxidase inhibition and noradrenaline and serotonin re-uptake blocade seems to be the most likely mechanism of action of SJW (see Nordfors, M. et al., 1997, Lakartidningen 94, 25, 2365-2367). A close relationship between folate metabolism and depression is well documented (see Alpert, J.E. et al., 1997, Nutrition Reviews 55, 5, 145-149). It is known that depressive symptoms are the most common indicator of folate deficiency. Depressed patients have been consistently found to have lower serum folate concentrations than control subjects (see Fava, M. et al., 1997, Am. J. Psychiatry 154, 426-428). Recently, low folate levels were linked to the poor response to selective serotonin uptake inhibitors. The biochemical mechanisms by which folic acid derivatives affect the neuro- psychiatric status apparently involve transmethylation reactions with components (DNA, RNA, proteins, biomembranes) of the central nervous system. The methyl group from folate (in the form of active metabolite 5- methyltetrahydrofolic acid, 5-MTHF, or 5-formyitetrahydrofolic acid, after be- ing reduced to 5-MTHF) is transferred to homocysteine to form methionine. The de novo synthesis of methionine requires vitamin B12, since it involves a reaction catalyzed by vitamin B12-dependent methionine synthetase. Methionine then participates in the reaction producing S-adenosylmethionine which is an important intermediate in more than 35 transmethylation reactions in CNS (see Bottiglieri, T. et al., 1994, Drugs 48, 137-152). Among reactions relevant to the effect of folate level on depression is the synthesis of tetrahy- drobiopterin, a cofactor in the hydroxylation of phenylalanine and tryptophan playing a crucial role in the biosynthesis of the neurotransmitters dopamine, norepinephrine and serotonin. The significant beneficial impact of the suggested composition on psychoneu- rological status is expected through a reduction of high levels of homocys- teine in the brain due to 5-methyl-tetrahydrofolic acid treatment. High levels of homocysteine have been recognized as a major risk factor for a wide range of diseases including neurological and cerebrovascular diseases. In particular, increased plasma homocysteine level has been linked to depression, mental and severe psychomotoric retardation. Among major causes of hyperhomocysteinemia are genetic deficiencies of methylenetetrahydrofolate reductase (MTHFR) or cystathionine β-synthase (CS), key enzymes in the metabolism of folic acid. Methylenetetrahydrofolate reductase deficiency is a relatively common disorder, and about 15 % of the general population have abnormal MTHFR genotype. A successful treatment of hyperhomocysteinemia with folic acid and cofactors of folic acid metabo- lism (e.g. vitamin B6 and vitamin B12) has been documented in numerous studies (see Bottiglieri, T., 1996, Nutrition Reviews 54, 12, 382-390). The active metabolite in the folic acid pathway is 5-methyltetrahydrofolic acid which, orally administered, should be more efficacious than folic acid. Folic acid given to the patients has to go through several reactions including a MTHFR catalyzed reaction to produce 5-methyltetrahydrofolic acid. All these steps can be by-passed with the direct introduction of 5-methyltetrahydrofolic acid. Of major importance is that 5-methyltetrahydrofolic acid is the only metabolite which is able to pass the blood-brain barrier. However, because of the possible conversion of other folic acid derivatives to 5- methyltetrahydrofolic acid, it is certainly possible to use for example 5- formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10- methylentetrahydrofolic acid, 5-methenyltetrahydrofolic acid, tetrahydrofolic acid, dihydrofolic acid and folic acid itself. Surprisingly it has been found that St. John's Wort, a traditional soft antide- pressant which improves the psychovegetative conditions by modulating the action of neurotransmitters, and 5-methyltetrahydrofolic acid which improves the psychiatric condition by a reduction of the homocysteine concentration in the brain augment their beneficial effect when used in combination. As the results of their synergistic effect, symptoms of depression are removed and also metabolic conditions of the central nervous system are improved. This leads to a decrease of intensity and frequency of attacks of depression. Therefore, the object of the present invention is an orally applicable natural formulation comprising St. John's Wort {Hypeήcum perforatum) or its extracts or active ingredients in combination with folic acid derivatives or suitable salts thereof. These natural formulations are highly useful for the prevention and the therapy of depression. The St. John's Wort may be used as the whole plant, its water extract, etha- nol or any other extract. It is also possible to use just one or more of the plants ingredients. Especially preferred is the hypericin which is commercially available in different concentrations (e.g. 0.3% Hypericin St. John's Wort, Fa. Lichtwer, Berlin). As the second ingredient folic acid derivatives selected from the group consisting of 5-methyltetrahydrofolic acid, tetrahydrofoiic acid, dihydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5,10- methylentetrahydrofolic acid and 5-methenyltetrahydrofolic acid or their suitable salts are used. 5-methyltetrahydrofolic acid or 5-formyltetrahydrofolic acid are especially preferred. The folic acid derivatives may also be in the form of their salts. Preferred are suitable salts like their sodium or calcium salts. In the case of application of 5-formyltetrahydrofolic acid, additional ingredients should be vitamin B12 and betaine anhydrous. Betaine is a donor for methyl groups which are transferred by vitamin B12 to homocysteine. Useful compositions may contain in one serving 400 to 5 000 meg of folic acid derivative and in case of 5-formyltetrahydrofolic acid 50 mg to 1 000 mg betaine and 0,5 to 10 meg vitamin B12. The dose of St. John's Wort can be adjusted to the particular case in a wide range. Preferably a commercially available extract of 0.3 % Hypericin is applied in an amount of 100 mg to 1000 mg. The formulations according to the present invention may be prepared in form of tablets, gelcaps, capsules or syrups. The compositions of the present invention preferably are useful as food supplements, but they may also be administered in a pharmaceutical treatment. The present invention makes available: a) a method of prevention of neurological and psychopathological diseases; b) a method of supporting a pharmacological treatment of neurological and psychopathological diseases; c) a method leading to a decrease of intensity and frequency of attacks of depression; d) a natural approach without any side effects for the prevention and treatment of depression; by oral administration of a formulation described above and/or related and suggested above modifications of this composition. Thus, this invention provides an innovative formulation based on natural ingredients useful for the prevention and treatment of depression. The combination of the natural compounds - St. John's Wort or its extracts or active ingredients and derivatives of dihydro- and tetrahydrofolic acid, derivatives thereof or corresponding salts - constitutes a unique and safe approach to the prevention and treatment of mild to moderate forms of depression without any side effects. The entire disclosure of all applications, patents and publications, cited above and below are hereby incorporated by reference. From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the in- vention to adapt it to various usages and conditions. Examples Example 1 A lower dosed formulation according to the invention is obtained by mixing the following components: 300 mg of 0.3 % Hypericin St. John's Wort (Fa. Lichtwer, Berlin) and 400 meg of 5-methyltetrahydrofolic acid calcium salt, formulated in gelcaps. Example 2 A higher dosed formulation is obtained by mixing 600 mg of 0.3 % Hypericin St. John's Wort and 800 meg of 5-methyltetrahydrofolic acid calcium salt, formulated in gelcaps. Example 3 A formulation according to the invention is obtained by mixing 300 mg of 0,3 % Hypericin St. John's Wort, 400 meg of 5-formyltetrahydrofolic acid calcium salt, 300 mg betaine anhydrous and 3 meg vitamin B12 (cyanocobalamin), formulated in gelcaps. Example 4 A higher dosed formulation is obtained by mixing 600 mg of 0,3 % Hypericin St. John's Wort, 800 meg of 5-formyltetrahydrofolic acid calcium salt, 600 mg betaine anhydrous and 6 meg vitamin B12 (cyanocobalamin), formulated in gelcaps.

Claims: Claims 1. Orally applicable natural formulation comprising St. John's Wort (Hypericum perforatum) or its extracts or active ingredients in combination with derivatives of dihydro- and tetrahydrofolic acid or suitable salts thereof. 2. Formulation according to claim 1 comprising Hypericin St. John's Wort in form of its water or alcohol extract. 3. Formulation according to claim 1 or 2 comprising a derivative of folic acid selected from the group consisting of 5-methyltetrahydrofolic acid, tetrahydrofolic acid, dihydrofolic acid, 5-formyltetrahydrofolic acid, 10- formyltetrahydrofolic acid, 5,10-methylentetrahydrofolic acid and 5- methenyltetrahydrofolic acid or their suitable salts. 4. Formulation according to claim 3 comprising 5-formyltetrahydrofolic acid or its salts which comprises additionally vitamin B12 and betaine anhydrous. 5. Formulation according to claims 1 to 4 in the form of a dosage unit, comprising 400 to 5000 meg of dihydro- or tetrahydrofolic acid derivatives. 6. Formulation according to claims 1 to 4 in the form of a dosage unit, comprising 400 to 5000 meg of 5-formyltetrahydrofolic acid or its salts, 50 mg to 2000 mg of betaine anhydrous and 0,5 to 10 meg of vitamin B12. 7. A method of using the formulation according to claim 1 which comprises employing the formulation of claim 1 as a food supplement. 8. Method of prevention of neurological and psychopathological diseases which comprises orally administering a formulation according to claim 1. 9. Method of supporting a pharmacolocigal treatment of neurological and psychopathological diseases which comprises orally administering a formulation according to claim 1.

Inventors: BUCHHOLZ HERWIG, DUDDA ANGELA, MEDUSKI JERZY, BUCHHOLZ, HERWIG, DUDDA, ANGELA, MEDUSKI, JERZY
Applicants: BUCHHOLZ HERWIG, DUDDA ANGELA, MEDUSKI JERZY, MERCK PATENT GMBH, BUCHHOLZ, HERWIG, DUDDA, ANGELA, MEDUSKI, JERZY
Application year: 1999
Main classification: A61K35
IPC codes: A61K31, A61K36, A61P25